 PRINCETON, N.J., Aug. 23, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the formulation of single-vial platform presentations of monovalent single antigen, bivalent two antigens and trivalent three antigens combinations of filovirus vaccine candidates. 